EMEA-001877-PIP03-17

  • Email
  • Help

Overview

Product details for -
Invented name-
Active substance

Fremanezumab

Decision numberP/0386/2017
PIP numberEMEA-001877-PIP03-17
Pharmaceutical form(s)Solution for injection
Condition(s)/indication(s)

Prevention of cluster headache

Route(s) of administrationIntravenous use; Subcutaneous use
PIP applicant

Teva GmbH
Tel. +491726277979
E-mail: info.era-clinical@teva.de

Decision typeP: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision